The importance of offering adult smokers a portfolio of potentially less harmful products

Similar documents
Heat-not-Burn Products: Scientific Assessment of Risk Reduction

What is combustion and why is the absence of combustion important for heat not burn products

Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data

Tobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment

How innovation will deliver a smokefree

Heated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences

Investor Day Reduced-Risk Products Lausanne, September 29, 2016

00:08 For decades our scientists have endeavoured to reduce the risks of tobacco use and continue to do so today. 00:15

Analysis and Evaluation of a Cross-Sectional Study IEA World Congress of Epidemiology 20 th August Saitama, Japan

PROCEDURE FOR GENERATION AND TESTING OF MAINSTREAM TOBACCO HEATING SYSTEM (THS or IQOS) AEROSOL USING A LINEAR SMOKING MACHINE

TOBACCO HARM REDUCTION:

Actual Use Study of the Potential Reduced-Risk Product (RRP): Tobacco Heating System (THS)

Remarks by. Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products. Mirek Zielinski President, Reduced-Risk Products

The concept that not all tobacco and nicotine products

Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re

Cardiovascular effects of nicotine vs. cigarette smoke

Communication on Progress 2016 United Nations Global Compact

Next Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21

Lung Cancer Epidemiology & Prevention. A/Prof Fraser Brims

Air Quality assessment during indoor use of the Tobacco Heating System 2.2

Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery

Investor Day Lausanne, September 27, 2018

Sustainability Report 2017

Smoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017

JUUL and Other Emerging Tobacco Products. Emily McClelland, M.S. December 6, 2018

Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Aerosol System

CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING

CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING

ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE?

Investor Day Lausanne, September 27, 2018

The Latest on Vaping Among U.S. Teens

The IQOS Heating System

FDLI Annual Conference

RE: Docket No. FDA-2014-N , Electronic Cigarettes and the Public Health

Designing a Smoke-Free Future

Assessing the impact of Ploom TECH use on indoor air quality (IAQ)

Assessing Consumer Responses to RRP: Experience at PMI in Developing Fit-for-Purpose Self-Report Instruments

Global E-Cigarette Market- Industry Analysis & Outlook ( )

Aerosol Characterisation of e-cigarettes. Ross Cabot, Anna Koc, Caner U. Yurteri & John McAughey

Reduced-Risk Products Science Update

National Conference of State Legislatures Legislative Summit: Clearing the Air About E-Cigarettes

JTI Switzerland. JTI Schweiz 3

Philip Morris International s Position Statement on the Revision of the Tobacco Excise Directive. 14 February 2017

Should FDA try to move smokers to e-cigarettes or other less harmful tobacco-nicotine products and, if so, how?

E-Cigarettes: A Game Changer. Dr. Blake Brown Hugh C. Kiger Professor Agriculture and Resource Economics College of Agriculture & Life Sciences

The good, the bad and the ugly about the Foundation for a Smoke-Free World

E-Cigarettes: Current Perspective

The Emergence of JUULs and Heated Tobacco Products

The State of Smoking 2018 Global Survey Findings and Insights. Monday, March 19, 2018

Cancer and its Causes in Korea

AN UPDATE ON FDA S COMPREHENSIVE PLAN ON TOBACCO AND NICOTINE

Smoking and Non-Communicable Diseases in Hong Kong

The IQOS Heating System

Air Quality assessment during indoor use of the Tobacco Heating System 2.2

Recent Advances In Tobacco Science

Biomarker of Exposure Reductions Upon Switching for 5 Days from Cigarettes to a Carbon Heated Tobacco Product (CHTP 1.0)

UK E-Cigarette Summit Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures

JT Group Consolidated Financial Results 2018 First Quarter Results

Rationale for Establishing Tobacco Product Regulation

Investor Day Lausanne, June 21, André Calantzopoulos Chief Operating Officer Philip Morris International

Reduced Risk Review March Keith Lenghaus

Industry Post-Regulation. E-Cigarette Summit Tim Phillips, ECigIntelligence. 17 th November

E-Cigarettes and Vapes

Stop the Vape. Maria Hines RN, MSN. Denise Kneubuhler RN, MSN

Because PMI application did not report the full range of HPHCs in IQOS aerosol,

ONLINE AEROSOL ANALYSIS USING FTIR: ASSESSING CARBONYL YIELDS IN E-CIGARETTE AEROSOL

ΕΝΑΛΛΑΚΤΙΚΕΣ ΜΟΡΦΕΣ ΚΑΠΝΙΣΜΑΤΟΣ

Key Variables in Assessing ENDS Devices AND WHY THAT ISN T VOLTS

Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes

Raze-On. Tobacco 101

Discussion points on Bill S-5

Study Summary Study THS-PBA-02-US

The State of Smoking 2018 Global Survey Findings and Insights. Monday, March 19, 2018

A combination of licensed medication and professional support is four times more likely to achieve a stop in smoking behaviour.

Regulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.

E-Cigarette Update: Secondhand Vapour

The IQOS Heating System

FROM TOBACCO TO SOMETHING BETTER

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

FDA S CENTER FOR TOBACCO PRODUCTS: AN UPDATE ON REGULATORY ACTIVITIES AND PRIORITIES

Coach on Call. Thank you for your interest in E-Cigarettes: Your Questions Answered. I hope you find this tip sheet helpful.

Safety/risk assessment of electronic cigarettes

Peter G. Shields, MD Tobacco Products Scientific Advisory Committee (TPSAC) August 16, 2013

TOBACCO PLAYBOOK DÉJÀ VU: E-CIGARETTES MICHIGAN CANCER CONSORTIUM MARCH 26, 2014

Analysis of the Public's Perception on the Use of E- Cigarettes as an Alternative to Smoking

Multi-Country Opinion Research Survey TOPLINE RESULTS GLOBAL AVERAGE

Introduction. Principles

Electronic Nicotine Delivery Systems

Vontobel Viewpoints FDA New Direction on Tobacco Our Take

Electronic Cigarettes, Nicotine and Policy Implications

Tobacco-related risk perceptions in the regulation of tobacco products at the FDA Center for Tobacco Products

MARKETING STANDARDS FOR MEMBERSHIP

Electronic cigarette monaco

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

Investor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications

REGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING. Ron Borland PhD

Responsible Practice in E-Vapour Products (EVP) Product Stewardship

The Effect of Puff Profile and Volume on the Yields of E-Cigarettes

FORMs of TOBACCO. 2 nd of 3 Prep for Session 1

Transcription:

The importance of offering adult smokers a portfolio of potentially less harmful products International Symposium on Nicotine Technology June 15 th 2017 Thomas Mc Grath, PhD PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000 Neuchâtel, Switzerland (Part of Philip Morris International group of companies)

Reduced-Risk Products ( RRPs ) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. We have a range of RRPs in various stages of development, scientific assessment and commercialization. Because our products do not burn tobacco, they produce far lower quantities of harmful and potentially harmful compounds than found in cigarette smoke. 2

The Objective is Harm Reduction Offering adult smokers satisfying products that reduce the risk of smoking related diseases compared to continued smoking Harm Reduction Reduced-Risk Product = x Product Acceptance & Usage Smoking is addictive and causes a number of serious diseases Worldwide it is estimated that more than 1 billion people will continue to smoke in the foreseeable future* Successful harm reduction requires that adult smokers who would otherwise continue to smoke be offered a range of satisfying, scientifically substantiated, reduced risk products smokers can switch to completely * http://www.who.int/tobacco/publications/surveillance/reportontrendstobaccosmoking/en/index4.html Figure adapted from Clive Bates presentation to E-Cigarette Summit (19 Nov 2013) 3

Our ambition Our stated ambition is to convince all current adult smokers that intend to continue smoking to switch to smoke-free products as soon as possible. André Calantzopoulos, CEO Philip Morris International 4

Eliminating combustion is key The temperature at the burning tip > 600 C When air is drawn through the cigarette (i.e. during a puff) the temperature rises > 850 C The heat released breaks down tobacco components generating smoke and ash The cigarette smoke aerosol is a complex mixture of more than 6000 chemicals Baker R. R., 1975, Temperature variation within a cigarette combustion coal during the smoking cycle, High Temp. Sci., 7, 236 247). Coloration by PMI. Several of these chemicals are harmful and have been classified by public health authorities as likely causes of smoking related diseases. 5

RRPs: Our Portfolio of Alternative Products Heated Tobacco Products Products Without Tobacco Platform 1 Platform 3 Platform 2 Platform 4 Innovation in technology and rigorous scientific assessment Note: The products depicted are subject to ongoing development and therefore the visuals are illustrative and do not necessarily represent the latest stages of product development 6

Platform 1: Tobacco Heating System Controlled heating of tobacco to produce a nicotine containing tobacco vapor (aerosol) No burning (self-sustaining combustion) of the tobacco Significantly lower levels of harmful and potentially harmful constituents in the aerosol compared to cigarette smoke Patented HeatControl TM technology Battery Heater Circuit board Mouth Piece Tobacco 6 minutes of heating time or 14 puffs Aerosol collection with Health Canada Intense puffing regime (55 ml puff volume, 2 second puff duration, 30 second interval puff);comparison on a per-stick basis to the 3R4F reference cigarette. Reduction calculations exclude Nicotine, Glycerin and Total Particulate Matter. 7

Platform 2 Heat source is a pressed carbon tip Controlled heating of tobacco to produce a nicotine containing tobacco vapor (aerosol) Comparable look and feel to a cigarette, but it is not a cigarette Significantly lower levels of harmful chemicals and potentially harmful constituents in the aerosol compared to cigarette smoke Patented design completely separates the carbon tip from the tobacco and prevents the tobacco from burning Aerosol collection with Health Canada Intense puffing regime (55 ml puff volume, 2 second puff duration, 30 second interval puff);comparison on a per-stick basis to the 3R4F reference cigarette. Reduction calculations exclude Nicotine, Glycerin and Total Particulate Matter. 8

Platform 3 Novel innovation in nicotine aerosolization Unlike an e-cigarette, this product generates a nicotine-containing vapor (aerosol) in the form of a nicotine salt When a consumer draws on the mouth piece, a chemical reaction between nicotine (a weak base) and a weak organic acid takes place to produce a nicotine containing aerosol Nicotine + weak organic acid Nicotine salt The products depicted are subject to ongoing development and therefore the visuals are illustrative and do not necessarily represent the latest stages of product development. 9

Platform 4 New and innovative e-vapor product MESH vaporization technology generates a nicotine containing vapor (aerosol) by the controlled heating of a nicotine containing e-liquid Not based on coil and wick design Technology allows for: Consistent vapor delivery Low liquid detection Puff activation "Closed" system Manufacturing automation BATTERY MESH PRE-FILLED CAPSULE ACTIVATION BUTTON 10

Substantiating Reduced Risk: Totality of Scientific Evidence Post-Market Studies and Surveillance Consumer Perception and Behavior Assessment Clinical Trials Systems Toxicology Assessment Standard Toxicology Assessment Aerosol Chemistry and Physics Product Design and Control Principles Reduced Population Harm Reduced Exposure & Risk Reduced Risk in Laboratory Models Reduced Toxicity in Laboratory Models Reduced Formation of HPHCs Source: Smith, M.R., et al., Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the system and the scientific assessment program. Regulatory Toxicology and Pharmacology (2016). http://dx.doi.org/10.1016/j.yrtph.2016.07.006. HPHCs = Harmful or potentially harmful constituents 11

Independent Verification of PMI s Science Independent Studies Studies conducted by independent scientists Crowd-Sourced Verification Verification of methods and results using crowd-sourcing (sbvimprover.com) Expert Reports Verification of specific datasets Publish Study Results Peer-reviewed articles in scientific literature 12

Product Standard Principles Best health choice for smokers is to quit tobacco use altogether, and cessation should remain a key regulatory objective Successful harm reduction requires that adult smokers who intend to continue smoking be offered a range of satisfying, scientifically substantiated, reduced risk products smokers can switch to completely Regulation needs to let people hear and understand scientifically substantiated information about smoke-free alternatives Regulations should set the right standards on how innovative scientifically substantiated alternatives to cigarettes should be developed, assessed and manufactured 13

Product Acceptance and Usage high conversion rates to IQOS Converted ( 95% IQOS) December 2016 Adult Smoker Conversion Rates (%) 78 78 79 80 69 71 Predominant (70%-95% IQOS) 54 56 66 65 65 72 Source: Switzerland / Russia / Italy / Romania / Japan IQOS User Panels 15 15 12 13 14 8 Switzerland Russia Italy Romania Portugal Japan 14

Summary 1 2 Portfolio of alternative products 4 3 December 2016 Adult Smoker Conversion Rates (%) Converted ( 95% IQOS) Predominant (70%-95% IQOS) 69 71 78 78 79 80 54 56 66 65 65 72 We are committed to transparency and encourage independent verification of our results. 15 15 12 13 14 8 Switzerland Russia Italy Romania Portugal Japan 15

Our Portfolio Approach 2014 2015 2016 2017 Platform 1 City Tests National Geographic Expansion Platform 2 Final Phase of Development Clinical Trials City Test Platform 3 Product Development City Test Platform 4 (current generation) Nicocigs Acquisition Commercialization in Selected Geographies Platform 4 (next generation) E-Vapor Joint Research, Development & Technology Sharing Agreement with Altria City Test Heated Tobacco Products Products Without Tobacco 16

Over 2 million adult consumers have already stopped smoking and switched to IQOS Designing a Smoke-Free Future